Management of systemic lupus erythematosus in the coming decade: Potentials and challenges

APLAR Journal of Rheumatology

Volumn 9, Issue 4, 2006, Pages 419-424

  Chng, Hiok Hee ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Advances; Systemic lupus erythematosus; Therapy

Indexed keywords

ABATACEPT; ABETIMUS; ATLIZUMAB; AZATHIOPRINE; BELIMUMAB; BIOLOGICAL MARKER; CD20 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; EPRATUZUMAB; ETRATIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAKED DNA; PLACEBO; PREDNISONE; RITUXIMAB; SIMVASTATIN; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG COST; DRUG PULSE THERAPY; DRUG TARGETING; ECONOMIC ASPECT; GENE THERAPY; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONAL REGULATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOCYTE DEPLETION; MORTALITY; NONHUMAN; PATIENT ADVOCACY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RISK FACTOR; SMOKING; SOCIAL PSYCHOLOGY; STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM;

EID: 33750975335     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.00244.x     Document Type: Article

References (50)

1. Bongu A, Chang E, Ramsey-Goldman R (2002) Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol 16, 313-32.
2. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS (2001) Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93-6.
3. Mok CC, Mak A, Chu WP, To CH, Wong SN (2005) Long-term survival of southern Chinese patients with systemic lupus erythematosus: A prospective study of all age-groups. Medicine 84, 218-24.
4. Mok CC, Tang SSK (2004) Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 117, 791-5.
5. Urowitz MB, Feletar M, Bruce IN, Ebanez D, Gladman DD (2005) Prolonged remission in systemic lupus erythematosus. J Rheumatol 32, 1467-72.
6. Anolik JH, Aringer M (2005) New treatments for SLE: Cell depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 19, 859-78.
7. Weisendanger M, Stanevsky A, Kovsky S, Diamond B (2006) Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol 18, 227-35.
8. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA (2006) Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 65, 942-5.
9. Rönnblom L, Eloranta M-L, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54, 408-20.
10. Bruns A, Hostmann B, Feist E, Burmester G, Hiepe F (2006) Successful treatment of refractory cutaneous lesions with TNF-alpha blockers in two patients with lupus erythematosus. Ann Rheum Dis 65 (Suppl. II), 194 abstract [THU0255].
11. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50, 3161-9.
12. De Bandt M, Sibilia J, Le Loët X, Prouzeau S, et.al. and the Club Rhumatismes et Inflammation (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey. Arthritis Res Ther 7, 545-51.
13. Pavletic SZ, Illei GG (2005) The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 19, 839-58.
14. Tyndall A, Leblanc K (2006) Stem cells and rheumatology: Update on adult stem cell therapy in autoimmune diseases. Arthritis Rheum 55, 521-5.
15. Burt RK, Traynor A, Statkute L, et al. (2006) Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295, 527-35.
16. Tyndall A (2006) Allogeneic bone marrow transplantation for autoimmune disease - the jury is still out. J Rheumatol 33, 644-6.
17. Le Blanc K, Ringden O (2005) Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11, 321-34.
18. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R (2003) Therapy with statins in patients with refractory rheumatic diseases: A preliminary study. Lupus 12, 607-11.
19. Abeles AM, Pillinger MH (2006) Statins as antiinflammatory and immunomodulatory agents. A future in rheumatologic therapy? Arthritis Rheum 54, 393-407.
20. Roman MJ, Shanker B-A, Davis A, Lockshin MD (2003) Prevalence and correlates of accelerated atheroscleosis in systemic lupus erythematosus. N Engl J Med 349, 2399-406.
21. Tam L-S, Li EK, Wong C-K, Lam CWK, Li W-C, Szeto C-C (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: An open label trial. Ann Rheum Dis 65, 417-8.
22. Mok CC, Tong KH, To CH, Siu YP, Au TC (2005) Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int 68, 813-7.
23. Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P (2005) Lupus erythematosus with leflunomide: Induction or reactivation? Ann Rheum Dis 64, 153-5.
24. Dooley MA, Ginzler EM (2006) Newer therapeutic approaches for systemic lupus erythematosus: Immunosuppressive agents. Rheum Dis Clin North Am 32, 91-102.
25. Houssiau FA, Vasconcelos C, D'Cruz D (2002) Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46, 2121-31.
26. Contreras G, Pardo C, Leclercq B, et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350, 971-80.
27. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M (2006) Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15, 366-70.
28. Ginzler EM, Dooley MA, Aranow C, et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353, 2219-28.
29. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A (2006) Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15, 268-75.
30. Dammacco F (1994) Anti-dsDNA pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 9, 19-25.
31. Blank M, Nur I, Toub O, Maor A, Shoenfeld Y (2005) Towards molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol 29, 213-7.
32. Badsha H, Lian TY, Chan SP, Edwards CJ, Chng HH (2002) Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 11, 508-13.
33. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 353, 1711-23.
34. Majka DS, Holers VM (2006) Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 65, 561-3.
35. Beer S, Richter J, Willers R, Winkler-Rohlfing B, Schneider M (2006) Influence of cigarette smoking on disease activity and severity in SLE. Ann Rheum Dis 65 (Suppl. II), 193 Abstract [THU0252].
36. Marques-Deak A, Cizza G, Sternberg E (2005) Brain-immune interactions and disease susceptibility. Mol Psychiatry 10, 239-50.
37. Szyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoenfeld Y (2005) The neuroendocrine-immune interactions in systemic lupus erythematosus: A basis for understanding disease pathogenesis and complexity. Rheum Dis Clin North Am 31, 161-75.
38. Grimaldi CM (2006) Sex and systemic lupus erythematosus: The role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr Opin Rheumatol 18, 456-61.
39. Evans C, Whalen JD, Ghivizzani SC, et al. (1998) Gene therapy in autoimmune disease. Ann Rheum Dis 57, 125-7.
40. Chuzhin Y, Reddy B, Budhai L, et al. (1998) Prolonged survival in murine SLE by adenoviral mediated CTLA4Ig gene transfer. Arthritis Rheum 41, S140.
41. Kyttaris VC, Juang YT, Tsokos GC (2004) Gene therapy in systemic lupus erythematosus. Lupus 13, 353-8.
42. Evans WE, McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348, 538-49.
43. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348, 529-37.
44. Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in Systemic Lupus Erythematosus I. General overview of biomarkers and their applicability. Arthritis Rheum 50, 1709-20.
45. Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in Systemic Lupus Erythematosus II. Markers of disease activity. Arthritis Rheum 50, 2048-65.
46. Leong KP, Kong KO, Thong BYH, et al. (2005) Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 44, 1267-76.
47. Teh LS, McElhone K, Bruce I, et al. (2005) Development and validation of a disease specific quality of life measure for adults with systemic lupus erythematosus, the LupusQoL. Arthritis Rheum 52, S188 (Abstract) 424.
48. Yu EB, Shikiar R, Howard K, et al. (2006) Validation of Lup-QOL: A lupus-specific measure of health-related quality of life (HROL). Ann Rheum Dis 65 (Suppl. II), 601 Abstract [SAT0499].
49. Berrios-Rivera JP, Street RL Jr, Garcia Popa-Lisseanu MG, et al. (2006) Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 55, 385-93.
50. Hale ED, Treharne GJ, Lyons AC, et al. (2006) 'Joining the dots' for patients with systemic lupus erythematosus: Personal perspectives of health care from a qualitative study. Ann Rheum Dis 65, 585-9.